YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

Full Prescribing Information

Patient 1

Chronic Postsurgical Inflammation Diagnosis and Initial Treatments

  • check circle 1 Patient has a history of recurrent iritis and posterior uveitis with associated cystoid macular edema after ocular surgery OD that indicates chronic postsurgical inflammation
  • check circle 1 Initial treatment consists of:
  • navigation-next-4 Topical corticosteroid and nonsteroidal anti-inflammatory eye drops. No improvement.
  • navigation-next-4 An intravitreal steroid injection. Temporary improvement.
  • navigation-next-4 Short duration intravitreal corticosteroid implants. She improves for 6-14 weeks after treatments with VA between 20/25 and 20/30. But her symptoms, blurry vision, and loss of vision always recurs with VA deteriorating to between 20/70 and 20/150

How would you treat the patient?

Continue short-duration
corticosteroid implants

OR

Treat with YUTIQ

INDICATIONS AND USAGE

YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

IMPORTANT SAFETY INFORMATION

Contraindications

Ocular or Periocular Infections: YUTIQ is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases.

Hypersensitivity: YUTIQ is contraindicated in patients with known hypersensitivity to any components of this product.

Warnings and Precautions

Intravitreal Injection-related Effects: Intravitreal injections, including those with YUTIQ, have been associated with endophthalmitis, eye inflammation, increased or decreased intraocular pressure, and choroidal or retinal detachments. Hypotony has been observed within 24 hours of injection and has resolved within 2 weeks. Patients should be monitored following the intravitreal injection.

Steroid-related Effects: Use of corticosteroids including YUTIQ may produce posterior subcapsular cataracts, increased intraocular pressure and glaucoma. Use of corticosteroids may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses. Corticosteroids are not recommended to be used in patients with a history of ocular herpes simplex because of the potential for reactivation of the viral infection.

Risk of Implant Migration: Patients in whom the posterior capsule of the lens is absent or has a tear are at risk of implant migration into the anterior chamber.

Adverse Reactions

In controlled studies, the most common adverse reactions reported were cataract development and increases in intraocular pressure.

Please see full Prescribing Information.

This site is intended for US healthcare professionals only.

©2022 EyePoint Pharmaceuticals, Inc. All rights reserved.
480 Pleasant Street, Suite B300, Watertown, MA 02472

YUTIQ, the YUTIQ logo, and the EyePoint logo are registered trademarks of EyePoint Pharmaceuticals, Inc.

Contact Us|Terms and Conditions|Privacy Policy

04/2022 US-YUT-2200002

IMPORTANT SAFETY INFORMATION

Contraindications

Ocular or Periocular Infections: YUTIQ is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases.

IMPORTANT SAFETY INFORMATION

Contraindications

Ocular or Periocular Infections: YUTIQ is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases.